Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Buccal Drug Delivery System Market Grown from 2024 to 2025?

Recently, the scale of the buccal drug delivery system market has witnessed an accelerated expansion. The market size is projected to surge from $3.55 billion in 2024 to $3.91 billion in 2025, with a compound annual growth rate (CAGR) of 10.3%. This notable increase throughout the past years is credited to pioneering advancements in drug delivery, integration within the pharmaceutical sector, results from clinical trials and efficacy, strategic market penetration, and applications tailored to specific diseases.

What Growth Rate Is Anticipated for the Buccal Drug Delivery System Market in the Coming Years?

The market for buccal drug delivery systems is anticipated to expand significantly over the next several years, reaching a valuation of $5.97 billion in 2029, with a compound annual growth rate (CAGR) of 11.1%. This growth during the forecast period is due to factors like the emphasis on patient-focused drug administration, the increase in elderly population, the need for targeted treatments, biologics and peptides delivery, as well as regulatory backing and approvals, and investment in research and development. A few trends projected for this period are a focus on patient comfort and adherence, improvements in drug formulations, the rise of chronic illnesses, care for elderly and children, and improved drug bioavailability.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8290&type=smp

Who Are the Leading Companies in the Buccal Drug Delivery System Market?

Major companies operating in the buccal drug delivery system market are Teva Pharmaceuticals Industries Ltd., Pfizer Incorporated, GlaxoSmithKline Public Limited Company, Indivior PLC, Generex Biotechnology Corporation, Catalent Inc., Arx Limited Liability Company, BioDelivery Science International Incorporated, Cynapsus Therapeutics Incorporated, Endo Pharmaceuticals Public Limited Company, Medlab Clinical Ltd., AstraZeneca PLC, F Hoffmann-La Roche Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Novartis AG, Novo Nordisk A/S, Ethypharm SAS, Applied Pharma Research SA, Sunovion Pharmaceuticals Inc., Sanofi SA, Bayer AG, Adare Pharmaceuticals Inc., NAPP Pharmaceutical Ltd., Perrigo Company PLC, Reckitt Benckiser Group PLC, Teligent Pharma Inc., Par Pharmaceutical Companies Inc., Acorda Therapeutics Inc., Opiant Pharmaceuticals Inc.

What Are the Key Drivers of the Buccal Drug Delivery System Market?

Anticipations for the buccal drug delivery systems market’s growth are being fueled by the increasing prevalence of chronic diseases. Chronic diseases, typified by illnesses such as diabetes, cancer, arthritis, heart disease, and stroke, are persistent conditions that can last for a year or more. They require constant medical care and nutritional support as they can be managed but not cured. Buccal drug delivery systems offer an efficient route for delivering mucosal and transmucosal medications, which are needed by many patients dealing with chronic diseases such as cancer and diabetes. Based on data from the World Health Organization, a Switzerland-based UN subsidiary agency, in September 2023, chronic, or non-communicable diseases (NCDs) accounted for 74% of global deaths or 41 million fatalities. Breakdowns included 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Hence, the escalating prevalence of chronic diseases is stimulating the growth of the buccal drug delivery systems market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8290&type=smp

What Are the Key Market Segments in the Buccal Drug Delivery System Industry?

The buccal drug delivery system market covered in this report is segmented –

1) By Type: Sublingual, Buccal Tablets And Lozenges, Oral Sprays

2) By Application: Pain Management, Smoking Cessation, Angina Pectoris

3) By End-User: Hospitals, Ambulatory Centers, Other End-Users

Subsegments:

1) By Sublingual: Sublingual Tablets, Sublingual Films

2) By Buccal Tablets And Lozenges: Buccal Tablets, Buccal Lozenges

3) By Oral Sprays: Spray Solutions, Spray Gels

What Are the Latest Trends in the Buccal Drug Delivery System Market?

Key players in the buccal drug delivery systems market are striving to introduce innovative solutions like oral treatment options for plaque psoriasis, with the aim of enhancing patient outcomes and advancing the effectiveness of drug delivery systems. Plaque psoriasis, a chronic autoimmune disease, is marked by rapid skin cell growth, resulting in thick, red, and scaly patches. These oral treatments are designed to manage and alleviate the symptoms of this condition. For instance, in September 2022, the U.S. pharmaceutical giant, Bristol Myers Squibb, obtained FDA approval for Sotyktu (deucravacitinib), a new oral remedy for adults suffering from moderate-to-severe plaque psoriasis. This was a significant milestone given that it was the first novel oral therapy for the condition to be approved in nearly ten years. It provides a new mechanism of action as a selective inhibitor of tyrosine kinase 2 (TYK2).

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/buccal-drug-delivery-system-global-market-report

What Are the Key Regional Markets in the Buccal Drug Delivery System Industry?

North America was the largest region in the buccal drug delivery systems market share in 2024. The regions covered in the buccal drug delivery system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8290

This Report Delivers Insight On:

1. How big is the buccal drug delivery system market, and how is it changing globally?

2. Who are the major companies in the buccal drug delivery system market, and how are they performing?

3. What are the key opportunities and risks in the buccal drug delivery system market right now?

4. Which products or customer segments are growing the most in the buccal drug delivery system market?

5. What factors are helping or slowing down the growth of the buccal drug delivery system market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model